Cladribine and Ocrelizumab induce differentially modulated microRNA profiles in mononucleated blood cells from relapsing-remitting Multiple Sclerosis patients

被引：0
|
作者：
Arisi, Ivan [1 ]
Malimpensa, Leonardo [2 ]
Manzini, Valeria [2 ]
Brandi, Rossella [3 ]
D'Amelio, Chiara [4 ]
di Sturmeck, Tommaso Gosetti [1 ]
Crisafulli, Sebastiano [5 ]
Ferrazzano, Gina [2 ]
Belvisi, Daniele [2 ]
Malerba, Francesca [1 ]
Florio, Rita [1 ]
Pascale, Esterina [2 ]
Soreq, Hermona [6 ,7 ]
Salvetti, Marco [2 ]
Cattaneo, Antonino [1 ]
D'Onofrio, Mara [1 ]
Conte, Antonella [2 ]
机构：
[1] EBRI, European Brain Res Inst Rita Levi Montalcini, Rome, Italy
[2] Univ Roma La Sapienza, Rome, Italy
[3] Sci Dept Army Med Ctr, Rome, Italy
[4] Univ Cattolica Sacro Cuore, Rome, Italy
[5] Multiple Sclerosis Ctr, Milan, Italy
[6] Hebrew Univ Jersusalem, Edmond & Lily Safra Ctr Brain Sci, Jerusalem, Israel
[7] Hebrew Univ Jersusalem, Inst Life Sci, Jerusalem, Israel
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1415/1877
引用
收藏
页码：902 / 902
页数：1
相关论文
共 50 条
  • [31] Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions
    Huntemann, Niklas
    Mueller, Marc
    Masanneck, Lars
    Baumgart, Romy
    Axhausen, Franziska
    Wolff, Stephanie
    Kutsojannis, Bela
    Koelsche, Tristan
    Korsen, Melanie
    Pfeuffer, Steffen
    Meuth, Sven
    Pawlitzki, Marc
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 90 - 91
  • [32] Apoptosis of peripheral blood lymphocytes in patients with relapsing-remitting multiple sclerosis
    Petelin, Z
    Brinar, V
    Petravic, D
    Zurak, N
    Dubravcic, K
    Batinic, D
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S172 - S173
  • [33] A broad effect of ocrelizumab on the peripheral immune component in patients with early relapsing-remitting multiple sclerosis
    Garcia, A.
    Morille, J.
    Shah, S.
    Le Frere, F.
    Nicot, A.
    Berthelot, L.
    Wiertlewski, S.
    Gourraud, P. -A.
    Raposo, C.
    Bakdache, F.
    Buffels, R.
    Laplaud, D. -A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 593 - 594
  • [34] Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study
    de Antonio, Luis A. Rodriguez
    Cuberta-Gonzalez, Ines
    Garcia-Castanon, Inmaculada
    Oreja-Guevara, Celia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 69
  • [35] Ocrelizumab modifies circulating immune asset in relapsing-remitting multiple sclerosis subjects
    Abbadessa, Gianmarco
    Bruzzaniti, Sara
    Miele, Giuseppina
    Piemonte, Erica
    Signoriello, Elisabetta
    Lus, Giacomo
    Matarese, Giuseppe
    Galgani, Mario
    Bonavita, Simona
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 21 - 21
  • [36] Assessment of the lymphocyte repertoire in relapsing-remitting multiple sclerosis patients treated with ocrelizumab: the ImmunoReMS study
    Esposito, Federica
    Ferre, Laura
    Mascia, Elisabetta
    Sorosina, Melissa
    Clarelli, Ferdinando
    Santoro, Silvia
    Giordano, Antonino
    Cannizzaro, Miryam
    Moiola, Lucia
    Martinelli, Vittorio
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 815 - 815
  • [37] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria de Fransesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    Applied Health Economics and Health Policy, 2019, 17 : 857 - 873
  • [38] BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S205 - S205
  • [39] Shorter infusion time of ocrelizumab: results from the ensemble plus study in patients with relapsing-remitting multiple sclerosis
    Brochet, B.
    Berger, T.
    Bermel, R.
    Freedman, M.
    Hartung, H. P.
    Holmoy, T.
    Killestein, J.
    Ross, A. Perrin
    Buffels, R.
    Garas, M.
    Kadner, K.
    Schneble, H. -M.
    Wang, Q.
    Nos, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 307 - 308
  • [40] Cladribine is a safe and effective treatment for highly active relapsing-remitting multiple sclerosis
    Suslak, T.
    Macdougall, N.
    Murray, L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 269 - 269
12345